Memantine for the Prevention of Radiation Induced Cognitive Dysfunction in Brain Metastatic Patients; A Randomized Placebo-Controlled Trial

Amrita Institute of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年3月4日

试验速览

暂无简介。

•Patients of either gender aged 18 years and older.
•Patients must have a pathologically proven diagnosis of solid malignancy with brain metastases visible on contrast-enhanced- MRI (or CT for patients unable to have an MRI).
•Patient is able (i.e., sufficiently fluent) and willing to complete the cognitive function test and the quality-of-life questionnaires either in English or Malayalam
•ECOG performance status 0, 1, or 2.
•Serum creatinine must be <3g/dl within 28 days prior to registration.
•No memantine allergy
•No current alcohol or drug abuse
•No chronic use of benzodiazepines
•No severe active comorbidity

•Patients who are not willing to participate in the study
•Patients who have psychiatric illness, drug abuse, mental retardation (premorbid intelligence quotient <70)
•Prior cranial external beam radiotherapy
•Current use of NMDA antagonists, such as amantadine, ketamine, or dextromethorphan.
•Diagnosis of chronic liver disease/cirrhosis of the liver (e.g., Child-Pugh class B or C).
•Positive serum pregnancy test

发起方